苏州开拓药业股份有限公司 KINTOR
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
GT20029 China Phase II Trial For AGA Reached Primary Endpoint 2024-04-22 09:53
Study of Kintor's c-Myc Degrader Published in Subsidiary Journal of Nature 2024-03-14 12:22
Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China 2023-10-11 17:20
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China 2023-08-22 17:13
Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA 2023-07-19 21:03
Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US 2023-05-11 23:30
Kintor Pharma Announces 2022 Annual Results and Recent Business Progress 2023-03-31 00:33
Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China 2023-03-28 21:41
Kintor Pharma's KX-826 and GT20029 for Treatment of Androgenetic Alopecia (AGA) and Acne Presented at AAD 2023 2023-03-21 15:22
Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound 2023-02-10 21:19
Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met 2022-12-01 19:30
Kintor Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual c-Myc/GSPT1 Degrader GT19715 2022-11-10 09:12
Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US 2022-10-27 21:22
Kintor Pharma Announces Publication of Phase Ib Data from Pruxelutamide for AR+ mBC in EJC 2022-09-29 14:22
Kintor Announces 2022 Interim Results and Recent Business Update 2022-08-30 00:19
Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China 2022-08-09 17:00
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US 2022-08-03 19:38
Kintor Pharma and Etana's Collaboration on Pruxelutamide's COVID-19 Project Awarded with Belt and Road Innovation Project and Fund Support from the Science and Technology Department of Jiangsu Province 2022-06-14 12:35
Kintor Pharma Included in MSCI China Index 2022-05-15 18:28
Kintor Pharma Announces First Patient Dosing in Multi-Regional Global Phase II Clinical Trial of ALK-1 Antibody and Nivolumab Combination Therapy for the Treatment of Advanced Hepatocellular Carcinoma 2022-05-04 20:36
1 2 3